Abstract
INTRODUCTION:Stroke is one of the most prevalent cardiovascular events in the world, in Colombia it is the second cause of death and first in disability. One of the most important risk factors to consider is cholesterol control, the reduction of LDL-C and cholesterol levels, mainly through treatment with statins and other lipid-lowering drugs.
MATERIALS AND METHODS:The most relevant information on the use and benefits of this treatment and some additional considerations have been collected in this narrative review of the literature.
CONCLUSION:The results of this narrative review show the protective effect of this therapy when it is possible to reduce LDL-C and cholesterol levels, in addition to other therapies such as ezetimibe or PSCK9 inhibitors. On the other hand, studies mention possible beneficial effects in the context of stroke but more clinical trials are required.
References
Vos T, Lim S, Abbafati C, Abbas K, Abbasi M, Abbasifard M et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204-1220. DOI: 10.1016/S0140-6736(20)30925-9
Ministerio de Salud, Instituto Nacional de Salud, Observatorio Nacional de Salud. Carga de enfermedades por enfermedades crónicas no transmisibles y discapacidad en Colombia. Observatorio Nacional de Salud. 2015;5:38-51.
Ma Y, Li Z, Chen L, Li X. Blood lipid levels, statin therapy and the risk of intracerebral hemorrhage. Lipids Health Dis. 2016;15(1). DOI: 10.1186/s12944-016-0213-8
Goldstein L, Amarenco P, Zivin J, Messig M, Altafullah I, Callahan A et al. Statin Treatment and Stroke Outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial. Stroke. 2009;40(11):3526-3531. DOI: 10.1161/STROKEAHA.109.557330
Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006; 48:438-45. DOI: 10.1016/j.jacc.2006.04.070
Trajkovska K, Topuzovska S. High-density lipoprotein metabolism and reverse cholesterol transport: strategies for raising HDL cholesterol. Anatol J Cardiol. 2017:149-153. DOI: 10.14744/AnatolJCardiol.2017.7608
Moore K, Tabas I. Macrophages in the Pathogenesis of Atherosclerosis. Cell. 2011;145(3):341-355. DOI: 10.1016/j.cell.2011.04.005
Carvajal Carvajal C. El endotelio: estructura, función y disfunción endotelial. Med Leg Costa Rica. 2017;34(2):90-100. ISSN 2215-5287
Libby P, Ridker P, Hansson G. Progress, and challenges in translating the biology of atherosclerosis. Nature. 2011;473(7347):317-325. DOI: 10.1038/nature10146
Vergallo R, Crea F. Atherosclerotic Plaque Healing. N Engl J Med. 2020;383(9):846-857. DOI: 10.1056/NEJMra2000317
Climent E, Benaiges D, Pedro-Botet J. Tratamiento hipolipemiante en la prevención secundaria de la enfermedad cerebro-vascular isquémica. Clínica e Investigación en Arteriosclerosis. 2020;32(4):175-182. DOI: 10.1016/j.arteri.2019.12.002
Stancu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med. 2001;5(4):378-387. DOI: 10.1111/j.1582-4934.2001.tb00172.x
Cappellari M, Deluca C, Tinazzi M, Tomelleri G, Carletti M, Fiaschi A et al. Does statin in the acute phase of ischemic stroke improve outcome after intravenous thrombolysis? A retrospective study. J Neurol Sci. 2011;308(1-2):128-134. DOI: 10.1016/j.jns.2011.05.026
Ridker P, Danielson E, Fonseca F, Genest J, Gotto A, Kastelein J, et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N Engl J Med. 2008;359(21):2195-2207. DOI: 10.1056/NEJMoa0807646
Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685-96. DOI: 10.1016/S0140-6736(04)16895-5.
Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009;8(5):453-463. DOI: 10.1016/S1474-4422(09)70058-4
Kleindorfer D, Towfighi A, Chaturvedi S, Cockroft K. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021;52(7). DOI: 10.1161/STR.0000000000000375
Grundy S, Stone N, Bailey A, Beam C, Birtcher K. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;139(25). DOI: 10.1016/j.jacc.2018.11.002
Dandapat S, Robinson J. Guidelines for Management of Hyper-lipidemia: Implications for Treatment of Patients with Stroke Secondary to Atherosclerotic Disease. Curr Neurol Neurosci Rep. 2016;16(3). DOI: 10.1007/s11910-016-0621-1
Spence J, Azarpazhooh M, Larsson S, Bogiatzi C, Hankey G. Stroke Prevention in Older Adults. Stroke. 2020;51(12):3770-3777.
Dawson J, Béjot Y, Christensen L, De Marchis G, Dichgans M, Hagberg G et al. European Stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack. Eur Stroke J. 2022;7(3):I-XLI. DOI: 10.1177/23969873221100032
Hamilton P. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1721. DOI: 10.1056/NEJMoa1615664
Ascaso J, Civeira F, Guijarro C, Miranda J, Masana L, Mostaza J et al. Indications of PCSK9 inhibitors in clinical practice. Recommendations of the Spanish Society of Arteriosclerosis (SEA), 2019. Clin Investig Arterioscler. 2019;31(3):128-139. DOI: 10.1016/j.arteri.2019.04.002
Pordy R, White H, Schwartz G, Alings M, Bhatt D, Bittner V, Chiang C, Diaz R, Edelberg J, Goodman S, Hanotin C, Harrington R, Jukema J, Kimura T, Kiss R, Lecorps G, Mahaffey K, Moryusef A, Szarek M, Roe M, Tricoci P, Xavier D, Zeiher A and Steg G. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trialf. J Clin Lipidol. 2019;13(3):e54-e55. DOI: 10.1016/j.jacc.2018.10.039
Sabatine M, Giugliano R, Wiviott S, Raal F, Blom D, Robinson J, Ballantyne C, Somaratne R, Legg J, Wasserman S, Scott R, Koren M and Stein E, 2015. Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events. N Engl J Med. 2015; 372(16):1500-1509. DOI: 10.1056/NEJMoa1500858
Baigent, C., Keech, A., Kearney, P. M., Blackwell, L., Buck, G., Pollicino, C., Kirby, A, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493). DOI: 10.1016/S0140-6736(05)67394-1
De Caterina R, Scarano M, Marfisi R, Lucisano G, Palma F, Tatasciore A et al. Cholesterol-Lowering Interventions and Stroke. J Am Coll Cardiol. 2010;55(3):198-211. DOI: 10.1016/j.jacc.2009.07.062
Wang C, Wang Y, Li Z, Wang Y. The Management of LDL Cholesterol and Predictors of Goal Achievement in Stroke Patients in China: A Cross-Sectional Study. CNS Neurosci Ther. 2016;22(7):577-583. DOI: 10.1111/cns.12543
Tramacere I, Boncoraglio G, Banzi R, Del Giovane C, Kwag K, Squizzato A et al. Comparison of statins for secondary prevention in patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysis. BMC Med. 2019;17(1). DOI: 10.1186/s12916-019-1298-5
Yoshimura S, Uchida K, Daimon T, Takashima R, Kimura K, Morimoto T et al. Randomized Controlled Trial of Early Versus Delayed Statin Therapy in Patients With Acute Ischemic Stroke. Stroke. 2017;48(11):3057-3063. DOI: 10.1161/STROKEAHA.117.017623
Montaner J, Chacón P, Krupinski J, Rubio F, Millán M, Molina C et al. Simvastatin in the acute phase of ischemic stroke: a safety and efficacy pilot trial. European Journal of Neurology. 2008;15(1):82-90. DOI: 10.1111/j.1468-1331.2007.02015.x
Mullard A, Reeves M, Jacobs B, Kothari R, Birbeck G, Maddox K et al. Lipid Testing and Lipid-Lowering Therapy in Hospitalized Ischemic Stroke and Transient Ischemic Attack Patients. Stroke. 2006;37(1):44-49. DOI: 10.1161/01.STR.0000195127.12990.43
Amarenco, M.D P, Bogousslavsky, M.D. J, Callahan, III, M.D. A, B. Goldstein L, Hennerici M, E. Rudolph, Ph.D. A et al. High-Dose Atorvastatin after Stroke or Transient Ischemic Attack. N Engl J Med. 2006;355(6):549-559. DOI: 10.1056/nejmoa061894
Amarenco P, Benavente O, Goldstein L, Callahan A, Sillesen H, Hennerici M et al. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial by Stroke Subtypes. Stroke. 2009;40(4):1405-1409. DOI: 10.1161/STROKEAHA.108.534107
Amarenco P, Goldstein L, Messig M, O'Neill B, Callahan A, Sillesen H et al. Relative and Cumulative Effects of Lipid and Blood Pressure Control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trial. Stroke. 2009;40(7):2486-2492. DOI: 10.1161/STROKEAHA.108.546135
Tziomalos K, Athyros V, Karagiannis A, Mikhailidis D. Dyslipidemia as a Risk Factor for Ischemic Stroke. Curr Top Med Chem. 2009;9(14):1291-1297. DOI: 10.2174/156802609789869628
Amarenco P, Kim J, Labreuche J, Charles H, Abtan J, Béjot Y et al. A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. NEJM. 2020;382(1):9-19.
Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681. DOI: 10.1016/S0140-6736(10)61350-5
Safety profile of high-dose statin therapy in geriatric patients with stroke. doi: 10.1097/SMJ.0000000000000024. https:// www-ncbi-nlm-nih-gov.ezproxy.uniandes.edu.co:8443/pubmed/24305522.
Tirschwell D, Smith N, Heckbert S, Lemaitre R, Longstreth W, Psaty B. Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology. 2004;63(10):1868-1875. DOI: 10.1212/01.wnl.0000144282.42222.da
Chen Y, Li C, Yang C, Liu C, Chen C, Sheu J et al. Low cholesterol level associated with severity and outcome of spontaneous intracerebral hemorrhage: Results from Taiwan Stroke Registry. PLOS ONE. 2017;12(4):e0171379. DOI: 10.1371/journal.pone.0171379
Zhang X, Liu J, Wang M, Qi Y, Sun J, Liu J et al. Twenty-year epidemiologic study on LDL-C levels in relation to the risks of atherosclerotic event, hemorrhagic stroke, and cancer death among young and middle-aged population in China. J Clin Lipidol. 2018;12(5):1179-1189.e4. DOI: 10.1016/j.jacl.2018.06.011
Dowlatshahi D, Demchuk A, Fang J, Kapral M, Sharma M, Smith E. Association of Statins and Statin Discontinuation With Poor Outcome and Survival After Intracerebral Hemorrhage. Stroke. 2012;43(6):1518-1523. DOI: 10.1161/STROKEAHA.111.645978
Salmoirago-Blotcher E, Hovey KM, Andrews CA, Robinson JG, Johnson KC, Wassertheil-Smoller S, et al. Statin use and risk of haemorrhagic stroke in a community-based cohort of postmenopausal women: an observational study from the Women's Health Initiative. BMJ Open. 2015;5(2):e007075. DOI: 10.1136/bmjopen-2014-007075.
Pan YS, Jing J, Wang YL, Zhao XQ, Song B, Wang WJ, et al. Use of statin during hospitalization improves the outcome after intracerebral hemorrhage. CNS Neurosci Ther. 2014; 20 (6): 548-55. DOI: 10.1111/cns.12274
Lin H, Tsai W, Lin J, Chang W, Huang C, Wang H et al. Adjunctive statin therapy reduces intracranial hemorrhage and 1-year mortality in patients with atrial fibrillation after acute ischemic stroke: A population-based epidemiological study from Taiwan. J Clin Neurosci. 2019;69:224-229. DOI: 10.1016/j.jocn.2019.07.045
Judge C, Ruttledge S, Costello M, Murphy R, Loughlin E, Alvarez-Iglesias A et al. Lipid Lowering Therapy, Low-Density Lipoprotein Level and Risk of Intracerebral Hemorrhage - A Meta-Analysis. J Stroke Cerebrovasc Dis. 2019;28(6):1703-1709. DOI: 10.1016/j.jstrokecerebrovasdis.2019.02.018
Li Y, Zhang B, Zhang L, Xie D, Li Y. Efficacy of Statin therapy in post-stroke seizure prophylaxis: Clues from an observational study of routine secondary prevention treatment. Seizure. 2019;71:185-189. DOI: 10.1016/j.seizure.2019.07.010
Yi X, Han Z, Wang C, Zhou Q, Lin J. Statin and Aspirin Pretreatment Are Associated with Lower Neurological Deterioration and Platelet Activity in Patients with Acute Ischemic Stroke. J Stroke Cerebrovasc Dis. 2017;26(2):352-359. DOI: 10.1016/j.jstrokecerebrovasdis.2016.09.030
Intensive versus Guideline Blood Pressure and Lipid Lowering in Patients with Previous Stroke: Main Results from the Pilot 'Prevention of Decline in Cognition after Stroke Trial' (PODCAST) Randomised Controlled Trial. PLOS ONE. 2017;12(1):e0164608. DOI: 10.1371/journal.pone.0164608.
Kang J, Kao L, Lin H, Tsai M, Chung S. Statin use increases the risk of depressive disorder in stroke patients: A population-based study. J Neurol Sci. 2015;348(1-2):89-93. DOI: 10.1016/j.jns.2014.11.013
Becker K, Tanzi P, Kalil A, Shibata D, Cain K. Early Statin Use is Associated with Increased Risk of Infection After Stroke. J Stroke Cerebrovasc Dis. 2013;22(1):66-71. DOI: 10.1016/j.jstrokecerebrovasdis.2011.06.008
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.